Skip to Content

Fidelity Select Biotechnology FBIOX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 18.96  /  +0.85 %
  • Total Assets 4.6 Bil
  • Adj. Expense Ratio
    0.720%
  • Expense Ratio 0.720%
  • Distribution Fee Level Low
  • Share Class Type No Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.44%
  • Turnover 51%

USD | NAV as of Feb 23, 2024 | 1-Day Return as of Feb 23, 2024, 11:14 PM GMT+0

Morningstar’s Analysis FBIOX

Will FBIOX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

An incline in its Process Pillar rating is the primary driver of Fidelity Select Biotechnology's upgrade to a Morningstar Medalist Rating of Bronze from Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBIOX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

12.96 596.1 Mil
Healthcare

Amgen Inc

7.95 365.5 Mil
Healthcare

Krystal Biotech Inc

5.35 246.3 Mil
Healthcare

Vertex Pharmaceuticals Inc

3.77 173.5 Mil
Healthcare

Regeneron Pharmaceuticals Inc

3.64 167.4 Mil
Healthcare

Alnylam Pharmaceuticals Inc

2.72 125.2 Mil
Healthcare

Biogen Inc

2.29 105.3 Mil
Healthcare

Ascendis Pharma A/S ADR

1.81 83.1 Mil
Healthcare

Biohaven Ltd

1.76 80.8 Mil
Healthcare

Fidelity Cash Central Fund

1.70 78.1 Mil
Cash and Equivalents